COR Q3 Earnings & Revenues Beat Estimates, '25 EPS View Raised

Cencora (COR) reported strong fiscal Q3 2025 results, with adjusted EPS of $4.00 beating estimates by 5.8% and rising 19.8% year-over-year, alongside revenues of $80.7 billion, up 8.7%. This performance was primarily driven by robust demand for GLP-1 drugs and specialty products within its U.S. Healthcare Solutions segment. Consequently, COR raised its full-year 2025 adjusted EPS guidance to $15.85-$16.00, reflecting confidence in its U.S. operations despite margin pressures from lower-margin GLP-1 sales and increased operating expenses.

Analysis

Cencora, Inc. (COR) reported a strong third-quarter fiscal 2025, with adjusted EPS of $4.00 beating consensus estimates by 5.8% and rising 19.8% year-over-year. This was driven by an 8.7% YoY increase in revenue to $80.7 billion, fueled primarily by its U.S. Healthcare Solutions segment. This core domestic business saw revenues grow 8.5% and operating income surge 29.1%, benefiting from high demand for GLP-1 drugs and specialty products. Reflecting this strength, the company raised its full-year adjusted EPS guidance to $15.85-$16.00, above the consensus estimate of $15.81, and lifted its adjusted operating income growth forecast to 15-16%. However, this positive picture is contrasted by weakness in the International Healthcare Solutions segment, where operating income fell 12.9% and its full-year guidance was revised to a steeper decline. Furthermore, while overall adjusted operating margins expanded 13 basis points, the company faces headwinds from the lower-margin profile of GLP-1 drugs. A notable concern is the significant drop in cumulative net cash from operating activities to $741.7 million from $2.48 billion a year ago, which, coupled with a slight 0.8% pre-market share price decline, suggests investors may be weighing these risks against the strong headline numbers.

Key Decisions for Investors

• Investors should weigh the outperformance of the U.S. Healthcare Solutions segment, which drove the upgraded FY25 guidance, against the deteriorating profitability in the International segment, where operating income guidance was cut.
• It is critical to scrutinize the substantial year-over-year decline in net cash from operating activities, as this could signal underlying working capital or profitability challenges not immediately apparent from the adjusted earnings beat.
• Monitor gross margin trends closely, as the reported negative impact from the growing sales mix of lower-margin GLP-1 drugs may increasingly pressure profitability despite the current overall margin expansion.
• Given the stock's 29.4% year-to-date gain, consider whether the positive earnings and guidance were already priced in, as suggested by the muted pre-market reaction.